Technical Analysis for AYTU - Aytu BioScience, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | -1.28% | |
| New Downtrend | Bearish | -1.28% | |
| Wide Bands | Range Expansion | -1.28% | |
| Oversold Stochastic | Weakness | -1.28% | |
| Stochastic Buy Signal | Bullish | -7.79% | |
| NR7 | Range Contraction | -7.79% | |
| Lower Bollinger Band Walk | Weakness | -7.79% | |
| Wide Bands | Range Expansion | -7.79% | |
| Oversold Stochastic | Weakness | -7.79% | |
| Hammer Candlestick | Bullish | -8.06% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 2 hours ago |
| Down 2 % | about 3 hours ago |
| Up 3% | about 3 hours ago |
| Down 1% | about 3 hours ago |
| Up 2% | about 3 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/13/2024
Aytu BioScience, Inc. Description
Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company's pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company, through its wholly-owned subsidiary Nuelle, Inc., is focused on women’s sexual wellbeing and intimacy.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Alcohol Prostate Cancer Urology In Vitro Hormones Fertility Ketones Imaging Agent Estrogen Infertility Testosterone Urinary Tract Infection In Vitro Diagnostic Device Androstanes Company's Pipeline Male Infertility Urinary Tract Infections
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.45 |
| 52 Week Low | 1.41 |
| Average Volume | 33,329 |
| 200-Day Moving Average | 2.69 |
| 50-Day Moving Average | 2.15 |
| 20-Day Moving Average | 1.82 |
| 10-Day Moving Average | 1.65 |
| Average True Range | 0.18 |
| RSI (14) | 24.24 |
| ADX | 25.75 |
| +DI | 9.38 |
| -DI | 23.85 |
| Chandelier Exit (Long, 3 ATRs) | 1.73 |
| Chandelier Exit (Short, 3 ATRs) | 1.95 |
| Upper Bollinger Bands | 2.21 |
| Lower Bollinger Band | 1.42 |
| Percent B (%b) | 0.09 |
| BandWidth | 43.71 |
| MACD Line | -0.18 |
| MACD Signal Line | -0.16 |
| MACD Histogram | -0.0163 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.69 | ||||
| Resistance 3 (R3) | 1.70 | 1.64 | 1.66 | ||
| Resistance 2 (R2) | 1.64 | 1.59 | 1.64 | 1.64 | |
| Resistance 1 (R1) | 1.56 | 1.56 | 1.54 | 1.56 | 1.63 |
| Pivot Point | 1.51 | 1.51 | 1.49 | 1.50 | 1.51 |
| Support 1 (S1) | 1.43 | 1.46 | 1.40 | 1.42 | 1.35 |
| Support 2 (S2) | 1.38 | 1.43 | 1.37 | 1.34 | |
| Support 3 (S3) | 1.30 | 1.38 | 1.33 | ||
| Support 4 (S4) | 1.29 |
